

Table S1. List of adjuvant therapies given to the patient cohort.

Primary Agent	Number of Patients	Associated Clinical Trials
CP-675,206 (Anti-CTLA-4)	1	NCT00431275
Dendritic Cell Vaccine	11	NCT00700167; NCT00124124
GP-100 + Tyrosinase	1	NCT00003362
GP75 DNA vaccine	1	NCT00034554
Interferon	8	N/A
NY-ESO-1	9	NCT00037037; NCT00142454; NCT00821652
Radiation	22	N/A
Sargramostim (GM-CSF)	3	N/A
Temodar	11	N/A

Table S2. List of clinical trials enrolling patients in the study cohort.

Clinical Trial Identifier	Number of Patients	Primary Agent	Summary of Inclusion Criteria
NCT00003362	1	GP100 + Tyrosinase	18 years and over; resected or unresectable stage III/IV melanoma
NCT00034554	1	GP75 DNA vaccine	18 years and over; high-risk stage III/IV melanoma
NCT00037037	4	NY-ESO-1	18 years and over; high-risk stage III/IV melanoma
NCT00124124	10	Dendritic cell vaccine	18 years and over; resected stage IIB, IIC, or III melanoma
NCT00142454	3	NY-ESO-1	18 years and over; resected stage IIB, IIC, or III melanoma
NCT00431275	1	CP-675,206 (Anti-CTLA-4)	18 years and over; resected stage III/IV melanoma
NCT00700167	1	Dendritic cell vaccine	18 years and over; stage III/IV melanoma
NCT00821652	2	NY-ESO-1	18 years and over; resected stage IIB, IIC, III, or IV melanoma